Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q)

Human Pathology

Volumn 44, Issue 3, 2013, Pages 346-356

  Geyer, Julia Turbiner ^a   Verma, Shalini ^a   Mathew, Susan ^a   Wang, Y Lynn ^a   Racchumi, Joelle ^a   Espinal Witter, Rosanny ^a   Subramaniyam, Shivakumar ^a   Knowles, Daniel M ^a   Orazi, Attilio ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

del(5q); Isolated 5q deletion; Karyotype; Lenalidomide; Myelodysplastic syndrome

Indexed keywords

JANUS KINASE 2;

ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW EXAMINATION; CHROMOSOME DELETION; CHROMOSOME DELETION 5Q; CLINICAL ARTICLE; DYSPLASIA; FEMALE; GENE MUTATION; HUMAN; KARYOTYPE; MALE; MEGAKARYOCYTE; MYELODYSPLASTIC SYNDROME; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE MARROW; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; KAPLAN-MEIER ESTIMATE; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SEQUENCE DELETION; THALIDOMIDE;

EID: 84873711387     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.05.022     Document Type: Article

References (43)

1. S. Heim, and F. Mitelman Chromosome abnormalities in the myelodysplastic syndromes Clin Haematol 15 1986 1003 1021
2. O. Pozdnyakova, P.M. Miron, and G. Tang Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities Cancer 113 2008 3331 3340
3. P. Bernasconi, C. Klersy, and M. Boni Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution Leukemia 19 2005 1424 1431
4. F. Sole, E. Luno, and C. Sanzo Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes Haematologica 90 2005 1168 1178
5. D. Haase, U. Germing, and J. Schanz New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Blood 110 2007 4385 4395
6. R. Hasserjian, M.M. Le Beau, and A.F. List Myelodysplastic syndrome with isolated del(5q) S. Swerdlow, E. Campo, N.L. Harris, WHO classification of tumours of haematopietic and lymphoid tissues 2008 IARC Lyon 102 103
7. H. Van den Berghe, J.J. Cassiman, G. David, J.P. Fryns, J.L. Michaux, and G. Sokal Distinct haematological disorder with deletion of long arm of no. 5 chromosome Nature 251 1974 437 438
8. J. Boultwood, S. Lewis, and J.S. Wainscoat The 5q - syndrome Blood 84 1994 3253 3260
9. A.A. Giagounidis, U. Germing, and S. Haase Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 Leukemia 18 2004 113 119
10. S. Lewis, D. Oscier, and J. Boultwood Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion Am J Hematol 49 1995 194 200
11. S.G. Holtan, R. Santana-Davila, and G.W. Dewald Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era Am J Hematol 83 2008 708 713
12. M.M. Patnaik, T.L. Lasho, and C.M. Finke WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations Leukemia 24 2010 1283 1289
13. P. Mathew, A. Tefferi, and G.W. Dewald The 5q - syndrome: a single-institution study of 43 consecutive patients Blood 81 1993 1040 1045
14. M. Mallo, J. Cervera, and J. Schanz Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q Leukemia 25 2011 110 120
15. A. List, G. Dewald, and J. Bennett Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 2006 1456 1465
16. A. List, S. Kurtin, and D.J. Roe Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 2005 549 557
17. B.L. Ebert, J. Pretz, and J. Bosco Identification of RPS14 as a 5q - syndrome gene by RNA interference screen Nature 451 2008 335 339
18. J.L. Barlow, L.F. Drynan, and D.R. Hewett A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q - syndrome Nat Med 16 2010 59 66
19. W. Ingram, N.C. Lea, and J. Cervera The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow Leukemia 20 2006 1319 1321
20. K. Foucar, D.S. Viswanatha, and C.S. Wilson D.W. King, Non-neoplastic disorders of bone marrow 2008 ARP Press Washington, DC
21. K. Foucar, K. Reichard, and D. Czuchkewski Bone marrow pathology 3rd ed. 2010 ASCP Press Chicago
22. D.E. Bauermeister Quantitation of bone marrow reticulin - a normal range Am J Clin Pathol 56 1971 24 31
23. A. Manoharan, R. Horsley, and W.R. Pitney The reticulin content of bone marrow in acute leukaemia in adults Br J Haematol 43 1979 185 190
24. L.G. Shaffer, M.L. Slovak, and L.J. Campbell ISCN 2009: an international system for human cytogenetic nomenclature 2009 S. Karger Publishing Basel
25. Q. Chen, P. Lu, A.V. Jones, N.C. Cross, R.T. Silver, and Y.L. Wang Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders J Mol Diagn 9 2007 272 276
26. Y.L. Wang, K. Vandris, and A. Jones JAK2 Mutations are present in all cases of polycythemia vera Leukemia 22 2008 1289
27. Nutritional anemia, report of a WHO scientific group: World Health Organization 1968. Report No. 405.
28. Common toxicity criteria 1999: http://www.eortc.be/services/doc/ctc/ ctcv20-4-30-992.pdf.
29. F. Le Bras, M. Sebert, and C. Kelaidi Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion - the GFM experience Leuk Res 35 2011 1444 1448
30. H. Kantarjian, S. O'Brien, and F. Ravandi The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer 115 2009 5202 5209
31. L.T. Washington, D. Doherty, A. Glassman, J. Martins, S. Ibrahim, and R. Lai Myeloid disorders with deletion of 5q as the sole karyotypic abnormality: the clinical and pathologic spectrum Leuk Lymphoma 43 2002 761 765
32. R. Santana-Davila, S.G. Holtan, and G.W. Dewald Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution Leuk Res 32 2008 407 411
33. L. Ades, S. Boehrer, and T. Prebet Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study Blood 113 2009 3947 3952
34. G. Gohring, A. Giagounidis, and G. Busche Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression Ann Hematol 89 2010 365 374
35. V. Eclache, A. Da Rocha, G. Le Roux, and P. Fenaux Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide Haematologica 93 2008 315 316
36. M. Jadersten, L. Saft, and A. Pellagatti Clonal heterogeneity in the 5q - syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression Haematologica 94 2009 1762 1766
37. R. Tehranchi, P.S. Woll, and K. Anderson Persistent malignant stem cells in del(5q) myelodysplasia in remission N Engl J Med 363 2010 1025 1037
38. D.P. Steensma, G.W. Dewald, and T.L. Lasho The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes Blood 106 2005 1207 1209
39. M. Boissinot, R. Garand, M. Hamidou, and S. Hermouet The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS) Blood 108 2006 1781 1782
40. M.M. Ceesay, N.C. Lea, and W. Ingram The JAK2 V617F mutation is rare in RARS but common in RARS-T Leukemia 20 2006 2060 2061
41. 9/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable Blood 109 2007 1334 1335
42. L. Sokol, G. Caceres, K. Rocha, K.J. Stockero, D.W. Dewald, and A.F. List JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones Leuk Res 34 2010 821 823
43. K.F. Wong, W.S. Wong, L.L. Siu, T.C. Lau, and N.P. Chan JAK2 V617F mutation is associated with 5q - syndrome in Chinese Leuk Lymphoma 50 2009 1333 1335